Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in three upcoming investor conferences in August and September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in three upcoming investor conferences in August and September 2025.
The company will participate in: the UBS Precision Medicine Summit with a panel discussion on August 14, the Wells Fargo Healthcare Conference with 1x1 investor meetings on September 4, and the Morgan Stanley Global Healthcare Conference with a fireside chat on September 10. Live and archived webcasts for the UBS and Morgan Stanley events will be available on the company's investor relations website.
Details
News Market Reaction – CTKB
On Aug 13, the first trading day after this news, CTKB closed 3.47% above the previous close.
Data tracked by StockTitan Argus for the Aug 13 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.
- UBS Precision Medicine Summit in Dana Point, CA
Panel discussion: New Dimensions in Proteomics and Cellular Research on Thursday, August 14, 2025, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time
- Wells Fargo Healthcare Conference in Boston, MA
Participating in investor 1x1 meetings on Thursday, September 4, 2025
- Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY
Fireside chat on September 10, 2025, at 7:00 a.m. Pacific Time /10:00 a.m. Eastern Time
Interested parties may access live and archived webcasts of the presentations for the UBS and Morgan Stanley events referenced above on the “Investors” section of the company website at: investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.